Citations

Clear

75 citation(s) found for "Lee, Hong".

Recommendations From the International Consensus Conference on Anemia Management in Surgical Patients (ICCAMS)
Shander, Aryeh , Corwin, Howard L., Meier, Jens , Bisbe, Elvira , Erhard, J., Faraoni, David , Farmer, Shannon L. , Hall, Tiffany , Hardy, Jean‐François, Hofmann, Axel , Lee, Cheuk‐Kwong, Leung, Tsin Wah, Ozawa, Sherri , Sathar, Jameela , Torres, Rosalio, Múñoz, Manuel , Auerbach, Michael , Blitz, Jeanna D. , Frank, Steven M. , Girelli, Domenico , Lee, Cheuk Kwong , Spahn, Donat R. , Warner, Matthew A.

Mayo Clinic

Annals of Surgery | September 22, 2022 | Volume: 277 | Issue: 4 | Pages: 581-590

10.1097/sla.0000000000005721 | PMID 36134567 Get It

Background: Perioperative anemia has been associated with increased risk of red blood cell transfusion and increased morbidity and mortality after surgery. The optimal approach to the diagnosis and management of perioperative anemia is not fully established. Objective: To develop consensus recommendations for anemia management in surgical patients. Methods: An international expert panel reviewed the current evidence and developed recommendations using modified RAND Delphi methodology. Results: The panel recommends that all patients except those undergoing minor procedures be screened for anemia before surgery. Appropriate therapy for anemia should be guided by an accurate diagnosis of the etiology. The need to proceed with surgery in some patients with anemia is expected to persist. However, early identification and effective treatment of anemia has the potential to reduce the risks associated with surgery and improve clinical outcomes. As with preoperative anemia, postoperative anemia should be treated in the perioperative period. Conclusions: Early identification and effective treatment of anemia has the potential to improve clinical outcomes in surgical patients.
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer’s disease: associations with β-amyloid-PET, neurodegeneration and cognition
Chatterjee, Pratishtha , Vermunt, Lisa , Gordon, Brian A. , Pedrini, Steve , Boonkamp, Lynn, Armstrong, Nicola J. , Luo, Jingqin , Singh, Abhay Kumar , Li, Yan , Sohrabi, Hamid R. , Taddei, Kevin , Berman, Sarah , Chhatwal, Jasmeer P. , Graff-Radford, Neill, Day, Gregory S. , Farlow, Martin, Fox, Nick C. , Goate, Alison , Hassenstab, Jason , Xiong, Chengjie , Perrin, Richard J. , Fagan, Anne M. , Morris, John C. , Gordon, Brian A , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Luo, Jingqin , Berman, Sarah , Boonkamp, Lynn , Molloy, Mark P. , Benzinger, Tammie L.S. , Morris, John , Karch, Celeste M. , Cruchaga, Carlos , Farlow, Martin R. , Lee, Jae Hong , McDade, Eric , Mori, Hiroshi , Sánchez‐Valle, Raquel , Schofield, Peter R. , Levey, Allan I. , Jucker, Mathias , Masters, Colin L. , Bateman, Randall J. , Martins, Ralph N. , Teunissen, Charlotte E.

Mayo Clinic

No container title available | July 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1752559/v2 Get It

Abstract Glial fibrillary acidic protein (GFAP) is a promising candidate blood-based biomarker for Alzheimer’s disease (AD) diagnosis and prognostication. The timing of its disease-associated changes, its clinical correlates, and biofluid-type dependency will influence its clinical utility. We evaluated plasma, serum, and CSF GFAP in families with autosomal dominant AD (ADAD), leveraging the predictable age at symptom onset to determine changes by stage of disease. Plasma GFAP elevations appear a decade before expected symptom onset, after β-amyloid accumulation and prior to neurodegeneration and cognitive decline. Plasma GFAP distinguished β-amyloid-positive from β-amyloid-negative ADAD participants and showed a stronger relationship with β-amyloid load in asymptomatic than symptomatic ADAD. Higher plasma GFAP was associated with the degree and rate of neurodegeneration and cognitive impairment. Serum GFAP showed similar relationships, but these were less pronounced for CSF GFAP. Our findings support a role for plasma GFAP as a clinical biomarker for β-amyloid-associated cognitive deterioration in AD.
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer’s disease: associations with β-amyloid-PET, neurodegeneration and cognition
Chatterjee, Pratishtha , Gordon, Brian A. , Boonkamp, Lynn , Armstrong, Nicola J. , Xiong, Chengjie , Li, Yan , Taddei, Kevin , Chhatwal, Jasmeer P. , Graff‐Radford, Neill R. , Farlow, Martin R. , Mori, Hiroshi , Perrin, Richard J. , Fagan, Anne M. , Gordon, Brian A , Vermunt, Lisa , Pedrini, Steve , Singh, Abhay Kumar , Sohrabi, Hamid R. , Molloy, Mark P. , Benzinger, Tammie L.S. , Morris, John C. , Karch, Celeste M. , Berman, Sarah , Day, Gregory S. , Fox, Nick C. , Goate, Alison , Hassenstab, Jason , Lee, Jae‐Hong , Xiong, Chengjie , McDade, Eric , Sánchez‐Valle, Raquel , Schofield, Peter R. , Jucker, Mathias , Masters, Colin L. , Bateman, Randall J. , Martins, Ralph N. , Teunissen, Charlotte E.

Mayo Clinic

No container title available | June 29, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1752559/v1 Get It

Abstract Glial fibrillary acidic protein (GFAP) is a promising candidate blood-based biomarker for Alzheimer’s disease (AD) diagnosis and prognostication. The timing of its disease-associated changes, its clinical correlates, and biofluid-type dependency will influence its clinical utility. We evaluated plasma, serum, and CSF GFAP in families with autosomal dominant AD (ADAD), leveraging the predictable age at symptom onset to determine changes by stage of disease. Plasma GFAP elevations appear a decade before expected symptom onset, after β-amyloid accumulation and prior to neurodegeneration and cognitive decline. Plasma GFAP distinguished β-amyloid-positive from β-amyloid-negative ADAD participants and showed a stronger relationship with β-amyloid load in asymptomatic than symptomatic ADAD. Higher plasma GFAP was associated with the degree and rate of neurodegeneration and cognitive impairment. Serum GFAP showed similar relationships, but these were less pronounced for CSF GFAP. Our findings support a role for plasma GFAP as a clinical biomarker for β-amyloid-associated cognitive deterioration in AD.
Abstract 3214: Risk of atrial fibrillation among women diagnosed with breast cancer
Jung, Won-Young, Henry‐Tillman, Ronda , Lee, Hong Seok , Naqvi, Tasneem Z. , Park, Yong‐Moon , Jung, Wonyoung, Yeo, Yohwan , Park, Sang Hyun , Han, Kyungdo , Shin, Dong Wook

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 3214-3214

10.1158/1538-7445.am2022-3214 Get It

Abstract Introduction: Individuals with cancer may be at higher risk of atrial fibrillation (AF). However, sufficient data are lacking in AF risk among breast cancer survivors, especially for the mid-to long-term risk of AF and the impact of cancer treatment on this association. We aimed to investigate the risk of incident AF in women diagnosed with breast cancer and evaluate the association by length of follow-up and breast cancer treatment. Methods: Using the Korean Health Insurance Service database, we studied 96,476 women who were diagnosed with breast cancer (aged≥20 years) without prior history of AF and breast cancer and underwent breast cancer surgery between January 2007 and December 2013. They were matched 1:3 to a cancer-free population (n=289,428) based on birth year and sex and were followed to the end of 2018. Using ICD-10 codes (I48.0 to I48.4, I.48.9), AF was defined when it was a discharge diagnosis or was verified more than twice in an outpatient clinic. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of AF associated with breast cancer relative to the cancer-free population, adjusting for age, income, and comorbidities including diabetes, hypertension and hyperlipidemia. Results: During a median follow-up of 6.8 years, AF developed in 2,105 women with breast cancer (3.2 per 1,000 person-years). Mean age at baseline among participants was 49.6 years. Having breast cancer was associated with increased risk of AF (HR, 2.04; 95% CI, 1.93-2.15). This association was stronger for women aged <50 years (HR, 3.98; 95% CI, 3.59-4.40). When we repeated analyses with lag periods of two years to explore the possibility of reverse causation and mid-to long-term risk of AF (n=91,370), the association was largely attenuated but remained significant (HR, 1.18; 95% CI, 1.09-1.28 for total women and HR, 1.60; 95% CI, 1.38-1.86 for women aged <50 years). However, no increased risk of AF was observed in women with breast cancer aged >65 years. Compared with no use of anthracyclines and taxanes, respectively, ever use of anthracyclines and taxanes was associated with increased risk of AF after further adjusting for other cancer treatment modalities including use of trastuzumab, radiotherapy, and endocrine treatment (HR, 1.25; 95% CI, 1.12-1.40 and HR, 1.37; 95% CI, 1.23-1.53, respectively). This association persisted only among women with breast cancer ever treated with anthracyclines when analysis was limited to those with two year-lag periods (HR, 1.23; 95% CI, 1.04-1.45). Conclusions: In this large-scale nationwide cohort study in South Korea, women with breast cancer had an elevated risk of incident AF, especially for women with breast cancer younger than 50 years, regardless of the length of follow-up. Our findings also suggest that cardiotoxic side effects of cancer treatment such as use of anthracyclines might increase both short-term and mid-to long-term risk of AF among women with breast cancer. Citation Format: Yong-Moon ("Mark") Park, Wonyoung Jung, Yohwan Yeo, Sang Hyun Park, Ronda Henry-Tillman, Hong Seok Lee, Tasneem Z. Naqvi, Kyungdo Han, Dong Wook Shin. Risk of atrial fibrillation among women diagnosed with breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3214.
The location of PSEN1 pathogenic variants in transmembrane vs. cytoplasmic domains may alter neurodegenerative and cognitive trajectories: Findings from the DIAN study
Fitzpatrick, Colleen , Chui, Helena C., Fagan, Anne M. , Farlow, Martin R. , Graff‐Radford, Neill R. , Mori, Hiroshi , Perrin, Richard J. , Salloway, Stephen , Xiong, Chengjie , Johnson, Keith A., Chhatwal, Jasmeer P. , DIAN, Schultz, Stephanie A. , Schultz, Aaron P. , Joseph‐Mathurin, Nelly , McDade, Eric , Klunk, William E. , Fox, Nick C. , Xiong, Chengjie , Hassenstab, Jason , Goate, Alison , Hanseeuw, Bernard , Lee, Jae‐Hong , Jucker, Mathias , Allegri, Ricardo , Benzinger, Tammie L.S. , Berman, Sarah , Chui, Helena C. , Cruchaga, Carlos , Gordon, Brian A. , Martins, Ralph N. , Noble, James M. , Sánchez‐Valle, Raquel , Schofield, Peter R. , Levey, Allan I. , Karch, Celeste M. , Johnson, Keith A. , Bateman, Randall J. , Sperling, Reisa Anne , DIAN

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.050864 Get It

AbstractBackgroundThough pathogenic variations in PSEN1 leading to Autosomal Dominant Alzheimer's disease (ADAD) are all highly penetrant, there is substantial inter‐individual variability in the rates of cognitive decline and biomarker change observed in ADAD. We hypothesized that this inter‐individual variability may be associated with the location of the pathogenic variant within PSEN1. We tested this hypothesis using biomarker and cognitive data from the Dominantly Inherited Alzheimer Network (DIAN) observational study.MethodPSEN1 pathogenic variant carriers [grouped based on whether their ADAD genotype affected transmembrane (PSEN1 TM; N = 125) or cytoplasmic (PSEN1 CY; N = 62) domains] and non‐carriers [NC; N = 176] enrolled in DIAN underwent clinical evaluation, multimodal neuroimaging, and lumbar puncture for collection of cerebrospinal fluid (CSF). Linear mixed effects models with a restricted cubic spline were used to determine cross‐sectional differences in clinical and biomarker measures between NC, PSEN1 TM, and PSEN1 CY groups, across the disease course (estimated years to symptom onset; EYO).ResultBackground characteristics are reported in Table 1. PSEN1 CY and PSEN1 TM groups had elevated β‐amyloid (PiB‐PET) and phosphorylated‐tau levels (CSF pTauT181) compared to NC, but these biomarker measures were not different between PSEN1 TM and CY groups (Figure 1a‐b). Additionally, the PSEN1 TM group had decreased glucose metabolism compared to NC but was similar to the PSEN1 CY group (Figure 1c). However, we observed that PSEN1 TM carriers had significantly smaller hippocampal volume, greater lateral ventricle volume, and greater cognitive impairment (Figure 1d‐f) across EYO as compared to PSEN1 CY carriers.ConclusionDespite similar β‐amyloid PET and CSF pTauT181 levels across EYO, individuals with pathogenic variants affecting transmembrane domains in PSEN1 may have more rapid progression of disease as measured by cognitive function and neurodegeneration as compared to those with variants affecting cytoplasmic domains. These results have implications both for understanding the heterogeneity in ongoing ADAD clinical trials and for better understanding the pathobiology of ADAD.
Late presentation of traumatic tricuspid valve regurgitation after motor vehicle accident managemed with valve replacement surgery: Role of 3D echocardiography
Lee, Hong Seok , Naqvi, Tasneem Z. , Lee, Hong

Mayo Clinic

Echocardiography | October 1, 2021 | Volume: 38 | Issue: 10 | Pages: 1813-1816

10.1111/echo.15193 | PMID 34596917 Get It

Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes
Doran, Graeme, Cheung, Tak-Hong, Yim, So‐Fan, Yu, Mei‐Yung, Thorner, Aaron R. , Pedamallu, Chandra Sekhar , Lau, Kei-Man, Ducar, Matthew D. , Wong, Raymond R.Y., Wang, Vivian W., Nag, Anwesha , Wollison, Bruce M. , Dalgarno, Audrey, Lee, Jacqueline Ho Sze , Yeung, Suet-Ying, Wong, Lo , Leung, Shuk-On A., Mu, Yi , Mok, Samuel C. , Crum, Christopher P. , Chiu, Rossa W. K. , Berkowitz, Ross S. , Wong, Yick‐Fu, Thorner, Aaron R , Ducar, Matthew D , Lee, Jacqueline H S , Mok, Samuel C , Chung, Tony K.H. , Yim, So Fan, Worley, Michael J. , Elias, Kevin M. , Ojesina, Akinyemi I. , Yeung, Suet Ying, Horowitz, Neil S. , Davis, Michelle , Leung, Shuk On Annie , Chan, Paul K.S. , Lawrence, Michael S.

Mayo Clinic

Cancers | June 28, 2021 | Volume: 13 | Issue: 13 | Pages: 3218

10.3390/cancers13133218 | PMID 34203201 Get It

Personalized treatment of genetically stratified subgroups has the potential to improve outcomes in many malignant tumors. This study distills clinically meaningful prognostic/predictive genomic marker for cervical adenocarcinoma using signature genomic aberrations and single-point nonsynonymous mutation-specific droplet digital PCR (ddPCR). Mutations in PIK3CA E542K, E545K, or H1047R were detected in 41.7% of tumors. PIK3CA mutation detected in the patient’s circulating DNA collected before treatment or during follow-up was significantly associated with decreased progression-free survival or overall survival. PIK3CA mutation in the circulating DNA during follow-up after treatment predicted recurrence with 100% sensitivity and 64.29% specificity. It is the first indication of the predictive power of PIK3CA mutations in cervical adenocarcinoma. The work contributes to the development of liquid biopsies for follow up surveillance and a possibility of tailoring management of this particular women’s cancer.
Segregation of functional networks is associated with cognitive resilience in Alzheimer’s disease
Ewers, Michael , Luan, Ying , Frontzkowski, Lukas , Rubinski, Anna , Dichgans, Martin , Hassenstab, Jason , Gordon, Brian A. , Chhatwal, Jasmeer P. , Xiong, Chengjie , Morris, John C. , Goate, Alison , Fagan, Anne M. , Berman, Sarah , Chui, Helena C., Cruchaga, Carlos , Farlow, Marty, Graff‐Radford, Neill R. , Martins, Ralph N. , Mori, Hiroshi , Perrin, Richard J. , Xiong, Chengjie , Fox, Nick C. , O’Connor, Antoinette , Salloway, Stephen , Danek, Adrian , Büerger, Katharina , Bateman, Randall J. , Habeck, Christian , Network, for the Alzheimer’s Disease Neuroimaging Initiative and the Dominantly Inherited Alzheimer, Vöglein, Jonathan , Gordon, Brian A , O'Connor, Antoinette , Stern, Yaakov , Franzmeier, Nicolai , Dichgans, Martin , Cruchaga, Carlos , Bateman, Randall J , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Neitzel, Julia , Schofield, Peter R. , Benzinger, Tammie L.S. , Karch, Celeste M. , McDade, Eric , Allegri, Ricardo , Chui, Helena C. , Jucker, Mathias , Lee, Jae‐Hong , Rossor, Martin N. , Stern, Yaakov , Franzmeier, Nicolai , Network, for the Alzheimer’s Disease Neuroimaging Initiative and the Dominantly Inherited Alzheimer

Mayo Clinic

Brain | March 12, 2021 | Volume: 144 | Issue: 7 | Pages: 2176-2185

10.1093/brain/awab112 | PMID 33725114 Get It

Abstract Cognitive resilience is an important modulating factor of cognitive decline in Alzheimer’s disease, but the functional brain mechanisms that support cognitive resilience remain elusive. Given previous findings in normal ageing, we tested the hypothesis that higher segregation of the brain’s connectome into distinct functional networks represents a functional mechanism underlying cognitive resilience in Alzheimer’s disease. Using resting-state functional MRI, we assessed both resting-state functional MRI global system segregation, i.e. the balance of between-network to within-network connectivity, and the alternate index of modularity Q as predictors of cognitive resilience. We performed all analyses in two independent samples for validation: (i) 108 individuals with autosomal dominantly inherited Alzheimer’s disease and 71 non-carrier controls; and (ii) 156 amyloid-PET-positive subjects across the spectrum of sporadic Alzheimer’s disease and 184 amyloid-negative controls. In the autosomal dominant Alzheimer’s disease sample, disease severity was assessed by estimated years from symptom onset. In the sporadic Alzheimer’s sample, disease stage was assessed by temporal lobe tau-PET (i.e. composite across Braak stage I and III regions). In both samples, we tested whether the effect of disease severity on cognition was attenuated at higher levels of functional network segregation. For autosomal dominant Alzheimer’s disease, we found higher functional MRI-assessed system segregation to be associated with an attenuated effect of estimated years from symptom onset on global cognition (P = 0.007). Similarly, for patients with sporadic Alzheimer’s disease, higher functional MRI-assessed system segregation was associated with less decrement in global cognition (P = 0.001) and episodic memory (P = 0.004) per unit increase of temporal lobe tau-PET. Confirmatory analyses using the alternate index of modularity Q revealed consistent results. In conclusion, higher segregation of functional connections into distinct large-scale networks supports cognitive resilience in Alzheimer’s disease.
Tricuspid valve regurgitation management with valve replacement Late Presentation of Traumatic Tricuspid Valve Regurgitation after Motor Vehicle Accident -- Role of 3D Echocardiography
Lee, Hong Seok , Naqvi, Tasneem Z.

Mayo Clinic

No container title available | February 23, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.161410780.09714167/v1 Get It

A 51-year-old unrestrained female driver with history of a high-speed motor vehicle accident had been followed due to progressively worsening tricuspid valve regurgitation (TR). Three dimensional (3D0 transesophageal echocardiogram (TEE) showed a TR jet through a perforation in the an avulsed anterior leaflet from the tricuspid valve and another central tricuspid TR jet regurgitation due to tricuspid leafletresulted from malcoaptation of the leaflets from tricuspid annulus annular dilatation.
Biphasic cortical macro‐ and microstructural changes in autosomal dominant Alzheimer's disease
Montal, Víctor , Pegueroles, Jordi , Bejanin, Alexandre , Alcolea, Daniel , Carmona‐Iragui, María , Clarimón, Jordi , Xiong, Chengjie , Cruchaga, Carlos , Graff‐Radford, Neill R. , Noble, James M. , Laske, Christoph , Salloway, Stephen , Ances, Beau M. , McDale, Eric, Bateman, Randall J. , Blesa, Rafael , Sánchez‐Valle, Raquel , Fortea, Juan , (DIAN), for the Dominantly Inherited Alzheimer Network, Pegueroles, Jordi , Bejanin, Alexandre , Alcolea, Daniel , Clarimón, Jordi , Schofield, Peter R , Blesa, Rafael , Sánchez-Valle, Raquel , Lleó, Alberto , Fortea, Juan , Cruchaga, Carlos , Bateman, Randall J , Xiong, Chengjie , Ances, Beau M , Vilaplana, Eduard , Lee, Jae‐Hong , Allegri, Ricardo , Karch, Celeste M. , Schofield, Peter R. , Benzinger, Tammie L.S. , Lleó, Alberto , (DIAN), for the Dominantly Inherited Alzheimer Network, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | November 16, 2020 | Volume: 17 | Issue: 4 | Pages: 618-628

10.1002/alz.12224 | PMID 33196147 Get It

Abstract INTRODUCTION A biphasic model for brain structural changes in preclinical Alzheimer's disease (AD) could reconcile some conflicting and paradoxical findings in observational studies and anti‐amyloid clinical trials. METHODS In this study we tested this model fitting linear versus quadratic trajectories and computed the timing of the inflection points vertexwise of cortical thickness and cortical diffusivity—a novel marker of cortical microstructure—changes in 389 participants from the Dominantly Inherited Alzheimer Network. RESULTS In early preclinical AD, between 20 and 15 years before estimated symptom onset, we found increases in cortical thickness and decreases in cortical diffusivity followed by cortical thinning and cortical diffusivity increases in later preclinical and symptomatic stages. The inflection points 16 to 19 years before estimated symptom onset are in agreement with the start of tau biomarker alterations. DISCUSSION These findings confirm a biphasic trajectory for brain structural changes and have direct implications when interpreting magnetic resonance imaging measures in preventive AD clinical trials.